Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "ED"

9938 News Found

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India
News | September 16, 2025

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India

Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB


Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
Drug Approval | September 15, 2025

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis


Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr
Healthcare | September 14, 2025

Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr

Shantived Hospital generated revenue of around Rs 50 crore in FY2025


Takeda appoints Rhonda Pacheco President of US Business Unit
People | September 13, 2025

Takeda appoints Rhonda Pacheco President of US Business Unit

Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO


VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications
News | September 12, 2025

VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications

CRISPR-based detection enables highly specific molecular recognition


Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment
News | September 11, 2025

Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment

The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions


Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
Digitisation | September 11, 2025

Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines